Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUTRENEO neoadjuvant durvalumab and tremelimumab trial in bladder cancer
2017-002246-68Phase 2Active
- Sponsor
- CRIS Cancer Foundation
- Start
- Jun 2018
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, tremelimumab and cisplatin in bladder cancer (2 arms), sponsored by CRIS Cancer Foundation. Started Jun 2018; status: active.
02
Drugs
durvalumabtremelimumabcisplatin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2017-002246-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002246-68.